Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Niguldipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 9/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 8/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 8/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 8/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 8/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 8/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.98 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.98 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.98 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexniguldipine SCHEMBL1228966 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL9001404 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL245993 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL245992 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29385244 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL29386264 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL724137 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Dexniguldipine SCHEMBL29615752 | 0.99 | ADRA1A (1.00) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| Niguldipine SCHEMBL3869443 | 0.98 | ADRA1A (0.98) | ADRA1AADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9386117 | 0.97 | ADRA1A (0.95) | ADRA1AADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | WASHINGTON UNIVERSITY (US) | 2022-05-19 | — | — | US | claimed |
| US-10512667-B2 | Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-12-24 | — | — | US | claimed |
| US-20180369321-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ADRENOCORTICAL ACTIVITY AND/OR EXCESSIVE STEROID PRODUCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-12-27 | — | — | US | claimed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-9320753-B2 | Organ arrest, protection and preservation | HIBERNATION THERAPEUTICS, A KF LLC (US) | 2016-04-26 | — | — | US | claimed |
| WO-2016029127-A1 | DOT1L INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-02-25 | — | — | WO | claimed |
| US-20130184231-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2013-07-18 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| US-20100298254-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2010-11-25 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| US-20060034941-A1 | Organ preconditioning, arrest, protection, preservation and recovery | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2006-02-16 | — | — | US | claimed |
| US-6955814-B1 | protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention by administering potassium channel opener or agonist and adenosine receptor agonist and local anesthetic | GLOBAL CARDIAC SOLUTIONS PTY LTD. (AU) | 2005-10-18 | — | — | US | claimed |
| US-20050171050-A1 | Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine | GLOBAL CARDIAC SOLUTIONS PTD. LTD. (AU) | 2005-08-04 | — | — | US | claimed |
| WO-2004056181-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056180-A1 | ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (1) | GLOBAL CARDIAC SOLUTIONS PTY LTD (AU) | 2004-07-08 | — | — | WO | claimed |
| EP-1168912-A4 | ORGAN ARREST, PROTECTION AND PRESERVATION | UNIV JAMES COOK (AU) | 2002-07-31 | — | — | EP | claimed |
| EP-1168912-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | James Cook University (AU) | 2002-01-09 | — | — | EP | claimed |
| WO-2000056145-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | JAMES COOK UNIVERSITY (AU) | 2000-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152228-A1 | COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE | VDAC1, SLC8B1, CACNA1G | ADRA1A 1497/4885ADRA2A 929/4885ADRA2B 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.